Literature DB >> 2342828

Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b.

J Amir1, X Liang, D M Granoff.   

Abstract

Sera from 3 of 30 adults vaccinated with Haemophilus influenzae type b polysaccharide vaccine (Hib PS) had poor complement-mediated bacterial activity despite the presence of anti-Hib PS antibody concentrations of 8.6 to 20.5 micrograms/mL. These "nonkiller" antibodies killed less than 0.4 log cfu/mL compared to greater than 3 logs with all but one of the other sera. To investigate the basis of this poor functional activity, we characterized in detail the IgG antibodies to Hib PS present in two of the nonkiller sera, and compared the results with two of the "killer" sera. The latter were selected based on comparable levels of total antibody to Hib PS. No consistent differences were found between the relative proportions of IgG or IgA antibody to total anti-Hib PS antibody, or the respective ratios of IgG1 to IgG2 antibody in the nonkiller and killer sera. IgG fractions, and IgG affinity purified antibody to Hib PS were prepared. When tested at 2 micrograms/mL of antibody, the IgG fractions from the two nonkiller sera had much lower bactericidal activity than the corresponding fractions from the killer sera (3 logs less killing), and the former also had lower complement-mediated opsonic activity (20 and 13% uptake by human PMN compared to 62 and 93%). These data show the striking variability in the functional activity of vaccine-induced antibody to Hib PS. Antibody functional activity is likely to be affected by a number of factors but one important variable appears to be avidity since the IgG anti-Hib PS antibody from the two nonkiller sera had 2- to 5-fold lower avidity than the IgG antibody from the two killer sera.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2342828     DOI: 10.1203/00006450-199004000-00008

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  26 in total

1.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

Authors:  Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold
Journal:  Blood       Date:  2013-07-12       Impact factor: 22.113

3.  Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Authors:  W D Zollinger; E E Moran; S J Devi; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

4.  Aging and the immune response to the Haemophilus influenzae type b capsular polysaccharide: retention of the dominant idiotype and antibody function in the elderly.

Authors:  A H Lucas; D C Reason
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Immunoglobulin allotypes and immunoglobulin G subclass responses to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in early-onset periodontitis.

Authors:  J I Choi; M H Ha; J H Kim; S J Kim
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

6.  Comparison of nonhuman primate antibodies against Haemophilus influenzae type b polysaccharide with human antibodies in oligoclonality and in vivo protective potency.

Authors:  K H Kim; M K Park; C C Peeters; J T Poolman; M H Shearer; R C Kennedy; M H Nahm
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  IGH V3-23*01 and its allele V3-23*03 differ in their capacity to form the canonical human antibody combining site specific for the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  Leyu Liu; Alexander H Lucas
Journal:  Immunogenetics       Date:  2003-07-04       Impact factor: 2.846

8.  An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  M A Hazlewood; D S Kumararatne; A D Webster; M Goodall; P Bird; M Daha
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

9.  Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide.

Authors:  M T Jelonek; S J Chang; C Y Chiu; M K Park; M H Nahm; J I Ward
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.